Weekly review: FDA news, hypertension studies, and more
Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, May 13, to Friday, May 17, 2024), and click on each link to read and watch anything you may have missed.
1.) FDA approves ALTUVIIIO updated label for bleed protection in children with hemophilia
The extended label approval is based on full evidence from the XTEND-Kids study.
Click here for the full article.
2.) FDA accepts sBLA for dupilumab to treat CRSwNP in patients aged 12 to 17 years
The federal agency has accepted the sBLA for Priority Review designation, with a target action date of September 15, 2024.
Click here for the full article.
3.) Children with hypertension at higher risk of associated major adverse cardiac events
Children with hypertension were at an increased risk of stroke, congestive heart failure, and other major adverse cardiac events compared to non-hypertensive individuals.
Click here for the full article.
4.) Did hypertension guidelines change practice patterns in primary care?
Even 6 years after publication, the investigative team stated it is unknown if the recommendations have led to changes in primary care.
Click here for the full article.
5.) Iron supplements ineffective at improving psychomotor development in breastfed babies
“We found no statistically significant effect of early iron supplementation on developmental scores at 24 and 36 months,” wrote the study investigators.
